Meiragtx Holdings plc MGTX 深 沪
等待开盘 11-03 09:30:00 美东时间
9.08
+0.350
+4.01%
华盛通- 最 高9.19
- 今 开8.74
- 成交量 31.87万股
- 最 低 8.58
- 昨 收 8.73
- 总市值 7.30亿
- 52周最高 9.4966
- 市盈率 静 --
- 换手率 0.40%
- 52周最低 4.55
- 委 比 86.67%
- 总股本 8044.75万
- 历史最高 30.23
- 量 比 0.97
- 振 幅 6.99%
- 历史最低 3.49
- 每 手 1
- 风险率 1.04%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 富国银行上调苹果目标价升至290美元；"卖出"！花旗下调NuScale Power、阿特斯太阳能评级
今日重点评级关注：摩根大通：维持Cogent Biosciences"超配"评级，目标价从30美元升至44美元；Piper Sandler：维持Vital Energy"中性"评级，目标价从16美元升至30美元
10-22 10:10
Raymond James Initiates Coverage On MeiraGTx Hldgs with Strong Buy Rating, Announces Price Target of $29
Raymond James analyst Christopher Raymond initiates coverage on MeiraGTx Hldgs (NASDAQ:MGTX) with a Strong Buy rating and announces Price Target of $29.
10-22 01:40
MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress
MeiraGTx presents two posters at ESGCT 2025 Annual Congress. Poster P0089 highlights novel AAV capsids developed for efficient intravitreal delivery, showing improved transduction efficiency in retinal cells and potential for treating ocular diseases. Poster P0170 discusses scaling up a perfusion-based AAV manufacturing process to 40L bioreactors, enhancing yield and reducing costs. The company emphasizes its advanced manufacturing capabilities a...
10-07 12:00
Chardan Capital Maintains Buy on MeiraGTx Hldgs, Maintains $35 Price Target
Chardan Capital analyst Daniil Gataulin maintains MeiraGTx Hldgs (NASDAQ:MGTX) with a Buy and maintains $35 price target.
08-15 19:29
MeiraGTx Reports Progress in Genetic Medicines Development
Meiragtx Holdings ( ($MGTX) ) has released its Q2 earnings. Here is a breakdown...
08-15 12:28
MeiraGTx Hldgs Q2 EPS $(0.48) Misses $(0.46) Estimate, Sales $3.691M Miss $8.003M Estimate
MeiraGTx Hldgs (NASDAQ:MGTX) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.46) by 5.03 percent. This is a 36.84 percent increase over losses of $(0.76) per share from
08-14 20:06
MeiraGTx Gains UK Approval for Hologen Transactions
Meiragtx Holdings ( ($MGTX) ) has issued an announcement. MeiraGTx Holdings plc...
06-26 20:29
MeiraGTx Hldgs Q1 EPS $(0.51) Misses $(0.45) Estimate, Sales $1.93M Miss $4.43M Estimate
MeiraGTx Hldgs (NASDAQ:MGTX) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0.45) by 13.33 percent. This is a 59.38 percent decrease over losses of $(0.32) per share from
05-13 21:50
MeiraGTx Announces It Has Been Granted FDA Regenerative Medicine Advanced Therapy Designation For AAV-GAD For Treatment Of Parkinson's Disease
- This RMAT designation is based on data from 3 clinical studies demonstrating the potential benefit of AAV-GAD as a one-time treatment for Parkinson's disease- RMAT designation includes the benefits of the
05-09 20:04
